Compare Commvault Systems Inc (CVLT) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Commvault Systems Inc vs Incyte Corporation — how do they compare? Commvault Systems Inc trades at $156.34 (market cap $6.25B), while Incyte Corporation trades at $112.77 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 3.7× Commvault Systems Inc's market cap, and Commvault Systems Inc is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Commvault Systems Inc for 17 Days and Incyte Corporation for 33 Days on average.
| CVLT | INCY | |
|---|---|---|
Market Cap | $6.25B | $22.85B |
Volume | 632,727 | 1,927,029 |
Sector | Technology | Health |
52-Week High | $176.52 | $129.93 |
52-Week Low | $75.18 | $83.80 |
Typical Hold Time | 17 Days | 33 Days |
Enterprise Value | $6.24B | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVLT trades at $157.25, up 4.64% today, with a bullish technical signal and strong institutional interest. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Recent news highlights include achieving AWS Data Competency and expanding FedRAMP High authorization, reinforcing its cyber resilience leadership.
The outlook is positive, supported by analyst consensus and recent strategic wins, though high valuation multiples and a projected decline in net profit margin for 2026 present risks. Upside potential exists if earnings momentum continues, but investors should weigh premium valuations against growth sustainability.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Commvault Systems Inc
Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.
Read more on CVLT →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
